- Home
- DTF vs EPIX Comparison
DTF vs EPIX Comparison
Compare DTF & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTF
- EPIX
- Stock Information
- Founded
- DTF 1991
- EPIX 2009
- Country
- DTF United States
- EPIX Canada
- Employees
- DTF N/A
- EPIX N/A
- Industry
- DTF Investment Managers
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- DTF Finance
- EPIX Health Care
- Exchange
- DTF Nasdaq
- EPIX Nasdaq
- Market Cap
- DTF 78.7M
- EPIX 75.9M
- IPO Year
- DTF N/A
- EPIX N/A
- Fundamental
- Price
- DTF $11.25
- EPIX $1.70
- Analyst Decision
- DTF
- EPIX Hold
- Analyst Count
- DTF 0
- EPIX 3
- Target Price
- DTF N/A
- EPIX $2.00
- AVG Volume (30 Days)
- DTF 21.1K
- EPIX 54.8K
- Earning Date
- DTF 01-01-0001
- EPIX 08-04-2025
- Dividend Yield
- DTF 3.64%
- EPIX N/A
- EPS Growth
- DTF N/A
- EPIX N/A
- EPS
- DTF 0.44
- EPIX N/A
- Revenue
- DTF N/A
- EPIX N/A
- Revenue This Year
- DTF N/A
- EPIX N/A
- Revenue Next Year
- DTF N/A
- EPIX N/A
- P/E Ratio
- DTF $24.34
- EPIX N/A
- Revenue Growth
- DTF N/A
- EPIX N/A
- 52 Week Low
- DTF $10.29
- EPIX $1.40
- 52 Week High
- DTF $11.19
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- DTF 60.00
- EPIX 48.47
- Support Level
- DTF $11.16
- EPIX $1.60
- Resistance Level
- DTF $11.23
- EPIX $1.73
- Average True Range (ATR)
- DTF 0.04
- EPIX 0.05
- MACD
- DTF 0.00
- EPIX -0.00
- Stochastic Oscillator
- DTF 92.86
- EPIX 44.44
About DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing primarily in a diversified portfolio of investment-grade tax-exempt obligations.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.